Jan. 13, 2026
At January 13, 2026, Dr. Chai Yan officially Joined Qurgen/Fuent (The Qurgen’s China subsidiary) as Senior Vice President of Business Development of Qurgen and the CEO of Suzhou Fuent Pharmaceutics. Also, he serves the Board Secretary to Accelerate the Company’s Strategic Advancement.
As the company enters the clinical stage, it requires not only scientific breakthroughs to pioneer new therapies to treat major human diseases but also demands strategic upgrade and robust execution. Prof. Jianjun Wang, Chairman of Qurgen Board, commented: “Qurgen is very happy to welcome Dr. Chai to join the company to lead the company’s strategic transformation and be responsible for business development, financing management, and the overall operations of Fuent Pharmaceutics. His extensive experience in corporate management and capital markets provide strong support for achieving the key corporate milestones and accelerating the company’s strategic advancement”.
Dr. Chai holds a master’s degree in international business management from the University of Nottingham (UK) and a Doctor of Business Administration (DBA) from Arizona State University (USA). Prior to joining Qurgen, Dr.Chai served as Principal at IQVIA, where he was responsible for strategic and commercialization consulting for biopharmaceutical companies, commercial outsourcing services, market access, public policy, and government affairs. Earlier in his career, Dr. Chai held analytical and investment roles at McKinsey & Company and Harvard University Alumni Endowment Foundation.
“I am honored to join Qurgen at this pivotal stage of the company’s development,” said Dr. Chai. “Qurgen has a solid scientific foundation, a clear clinical development pathway, and an exceptional team spanning clinical operations, innovative technology development, and drug manufacturing. Our mission is not only to demonstrate scientifically the value of our novel protein therapeutics, but also to communicate our groundbreaking potential in the capital markets. As a member of Qurgen management team, I will work closely with my colleagues to accelerate the company’s growth, improve operational efficiency, ensure resources are allocated to the high-value pipelines, and ultimately bring innovative treatment solutions to patients at soon as possible.”